Large HIV vaccine clinical trials that were based on the stimulation of CD8+ T cell response alone (Step (HVTN 502) and Phambili (HVTN 503), Phase IIb), and those that activated primarily type-specific antibody responses (Vax003 and Vax004, Phase III) have failed to confer protection against HIV infection[3]. This evidence concerns the gene CD8A and HIV infectious disease.